Top Markets
Coin of the day
Polaryx Therapeutics, Inc. Common Stock Polaryx Therapeutics, Inc. Common Stock

Polaryx Therapeutics, Inc. Common Stock

PLYX
Rank in Stocks #21586
Polaryx Therapeutics, Inc. functions as a biotechnology firm dedicated to... Polaryx Therapeutics, Inc. functions as a biotechnology firm dedicated to advancing small-molecule therapies for lysosomal storage and neurodegenerative conditions. Its developmental pipeline includes a trio of promising candidates: PLX-100, which combines PLX-200 with an ancillary supplement, targeting late infantile neuronal ceroid lipofuscinosis (LINCL) and related forms of NCL. PLX-200, a repurposed compound already utilized to address various diseases in both adult and pediatric populations. And PLX-300, derived from an edible plant, which works by activating PPARa to enhance the production of transcription factor EB. The company, established in 2014, maintains its base of operations in Paramus, New Jersey.
Share Price
$2.10
Last synced: 2026-08-21
Market Cap
$104.43M
Change (1 day)
-2.10%
Change (1 year)
-
Country
US
Trade Polaryx Therapeutics, Inc. Common Stock (PLYX)

Category

Earnings for Polaryx Therapeutics, Inc. Common Stock (PLYX)
Earnings in 2026 TTM: 0
According to Polaryx Therapeutics, Inc. Common Stock latest financial reports the company's current earnings are 0. In 2026 the company made an earning of 0, equal to its 2026 earnings that were of 0. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Polaryx Therapeutics, Inc. Common Stock from 2026 to 2026
Earnings at the end of each year
Year Earnings Change
Not enough data for the provided dates.
Earnings for similar companies or competitors
Company Earnings Earnings Difference Country
$5.27B -
US
$1.95B -
NL
$-3.09B -
US
$-4.02B -
AU
- -
CH